Clinical Practice Session
Liver-Kidney Connection: Time to Rethink Hepatorenal Syndrome
November 02, 2023 | 04:30 PM - 06:00 PM
Location: Room 201, Pennsylvania Convention Center
Session Description
Accumulating evidence on the pathophysiology of hepatorenal syndrome (HRS) has challenged the conventional model of liver-kidney connection. For example, emerging data point to the heart as the key mediator of untoward kidney effects in HRS. Reliable assessment of kidney function in lieu of various eGFRs and with cystatin C is also potentially changing the way we have defined this syndrome. We discuss the role of point-of-care ultrasound (POCUS) in assessment of volume status in HRS, as well as the benefits and risks of terlipressin therapy in HRS, in light of emerging data and new US Food and Drug Administration approval for this indication.
Learning Objective(s)
- Explain the emerging evidence on the contribution of cardiac dysfunction to HRS
- Characterize the role of POCUS in assessment of volume in HRS
- Summarize the new data on the benefits and risk of terlipressin therapy in HRS
- Discuss the impact of evolving methods for assessment of kidney function on HRS management
Learning Pathway(s)
- AKI and Critical Care
- Pharmacology
Moderators
Presentations
- Reliably Assessing Kidney Function in Cirrhosis: How Close Is the Light at the End of the Tunnel?
04:30 PM - 04:50 PM
- "HepatoCardioRenal" Syndrome: Heart as the Neglected Player in HRS
04:50 PM - 05:10 PM
- When a Physical Exam Needs a Boost: The Role of POCUS in Volume Management of HRS
05:10 PM - 05:30 PM
- Benefits and Risks of Terlipressin Therapy in HRS
05:30 PM - 05:50 PM
- Q&A
05:50 PM - 06:00 PM